CEO Vincent Angotti highlighted significant progress in the NEPHRO CRRT study, emphasizing the FDA-approved reduction in study size from 166 to 70 patients while maintaining 90% statistical power for ...

Editorial Note: Forbes Advisor may earn a commission on sales made from partner links on this page, but that doesn't affect our editors' opinions or evaluations. Most of us rely on some sort of ...

Due to the delays in activating new clinical sites, Talphera now anticipates study completion in the first half of 2026, moving back from its previous expectation of year-end 2025. The company is ...

Have you ever spent hours crafting a timeline chart, only to abandon it because it was too clunky, rigid, or just plain uninspiring? You’re not alone. Many tools promise sleek visuals but fall short ...